Dr Sally A Baker, MD | |
10120 S Eastern Ave #130, Hennerson, NV 89052 | |
(702) 487-6880 | |
(702) 473-5455 |
Full Name | Dr Sally A Baker |
---|---|
Gender | Female |
Speciality | Anesthesiology |
Location | 10120 S Eastern Ave #130, Hennerson, Nevada |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073807418 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | MD451187 (Pennsylvania) | Secondary |
207L00000X | Anesthesiology | MT199586 (Pennsylvania) | Secondary |
207L00000X | Anesthesiology | 16404 (Nevada) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Sally A Baker, MD 10120 S Eastern Ave #130, Hennerson, NV 89052 Ph: (702) 487-6880 | Dr Sally A Baker, MD 10120 S Eastern Ave #130, Hennerson, NV 89052 Ph: (702) 487-6880 |
News Archive
Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.
Ipsen announced today that its partner Inspiration Biopharmaceuticals Inc. (Inspiration) was notified by the Food and Drug Administration (FDA) that both clinical trials evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.
Today's successful close of the merger agreement between Merge Healthcare Incorporated and AMICAS, Inc. creates a leading medical imaging software and healthcare IT solutions provider with strong customer relationships, innovative solutions, significant cross selling capabilities, and a solid international presence.
In preliminary results, researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes new neurons to develop in the part of the brain where cells are lost in Parkinson's disease (PD).
Moderately elevated levels of insulin increase the levels of inflammatory markers and beta-amyloid in plasma and in cerebrospinal fluid, and these markers may contribute to Alzheimer's disease, according to a new study posted online today from Archives of Neurology, one of the JAMA/Archives journals.
› Verified 9 days ago